Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach

  • Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S265-S269. doi: 10.21037/tlcr.2018.09.10.
Sharon R Pine  1  2  3 ,  Bríd M Ryan  4
Affiliations
  • 1. Department of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • 2. Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • 3. Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • 4. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
PMID: 30393619 DOI: 10.21037/tlcr.2018.09.10
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-139047
    SW157765
    98.08%, GLUT8 Inhibitor
    target: GLUT
    Research Areas: Cancer